Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH
NCT03582293Phase 3Recruiting
- Sponsor
- University of Amsterdam
- Start
- Jun 2018
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic subdural hematoma (CSDH) comparing Tranexamic Acid with PLACEBO (2 arms). Primary endpoint: Number of patients requiring surgery for chronic subdural hematoma at 12 weeks. Started Jun 2018; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT03582293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03582293.